{
  "first_published_at": "2009-02-01", 
  "original_url": "http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON088132", 
  "title": "Toremifene (Fareston): risk of QT prolongation", 
  "tags": "{\"parsed_therapeutic\": [\"cancer\"], \"Audience:\": [\"Primary care\", \"Secondary care\"], \"Therapeutic area:\": [\"Cancer\"]}", 
  "_document_number": 274, 
  "label": null, 
  "icon": "http://www.mhra.gov.uk/home/images/MHRALook/img/dsu/adverse_icon.png", 
  "therapeutic_area": [
    "cancer"
  ], 
  "raw_html": "<div id=\"dsuArticleContent\">\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\t<h1><a name=\"maincontent\" id=\"maincontent\"></a>Toremifene (Fareston): risk of QT prolongation</h1>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<span class=\"ref\">Article date: February 2009</span> \r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element21)-->\r\n\t\t\t\t\t\t\t\t<!--A European assessment has concluded that toremifene is associated with a dosedependent increase in QT interval, which carries a risk of serious cardiac arrhythmia-->\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element21)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element22)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element22)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element13)-->\r\n\t\t\t\t\t\t\t\t<!--<p><strong>Toremifene</strong> (Fareston) is an oestrogen receptor antagonist. Currently it is not widely used in the UK, but remains a licensed option to treat hormone-dependent metastatic breast cancer in postmenopausal women.</p><p>A European assessment has concluded that toremifene is associated with a dose-dependent increase in QT interval, which carries a risk of serious cardiac arrhythmia. The Summary of Product Characteristics has been updated to include new contraindications and warnings.</p><p>To view updated product information, press release, and question and answer document, see the <a href=\"http://www.emea.europa.eu/\" target=\"_blank\" title=\"European Medicines Agency website\">European Medicines Agency website</a></p><p>&nbsp;</p><p><em>Article citation: Drug Safety Update February 2009, vol 1 issue 7: 7a.</em></p>-->\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element13)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!-- SS_BEGIN_SNIPPET(fragment7,1)-->\r\n\t\t\t\t\t\t\t\t<!-- call include to dynamically insert alt attributes into image tags within a wysiwyg element -->\r\n<!-- get a reference to the wysiwyg content -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n\t<p><strong>Toremifene</strong> (Fareston) is an oestrogen receptor antagonist. Currently it is not widely used in the UK, but remains a licensed option to treat hormone-dependent metastatic breast cancer in postmenopausal women.</p><p>A European assessment has concluded that toremifene is associated with a dose-dependent increase in QT interval, which carries a risk of serious cardiac arrhythmia. The Summary of Product Characteristics has been updated to include new contraindications and warnings.</p><p>To view updated product information, press release, and question and answer document, see the <a href=\"http://www.emea.europa.eu/\" target=\"_blank\" title=\"European Medicines Agency website\">European Medicines Agency website</a></p><p>&#160;</p><p><em>Article citation: Drug Safety Update February 2009, vol 1 issue 7: 7a.</em></p>\r\n\t\t\t\r\n\t\t\t\t\t\t\t\t<!-- SS_END_SNIPPET(fragment7,1)-->\r\n\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t", 
  "date_of_article": "2009-02-01", 
  "date_last_modified": "2010-08-04", 
  "_assets": [], 
  "_item_id": 274, 
  "summary": "", 
  "body": "Article date: February 2009\n\nToremifene (Fareston) is an oestrogen receptor antagonist. Currently it is not widely used in the UK, but remains a licensed option to treat hormone-dependent metastatic breast cancer in postmenopausal women.\n\nA European assessment has concluded that toremifene is associated with a dose-dependent increase in QT interval, which carries a risk of serious cardiac arrhythmia. The Summary of Product Characteristics has been updated to include new contraindications and warnings.\n\nTo view updated product information, press release, and question and answer document, see the [European Medicines Agency website](http://www.emea.europa.eu/)\n\nÂ \n\nArticle citation: Drug Safety Update February 2009, vol 1 issue 7: 7a.\n"
}